On Tuesday, the price of Moderna stock rose by 24%.
In a Phase 2 trial, the business Moderna announced early on Tuesday that combining their novel Combining Keytruda from Merck’s normal dosage with a messenger RNA-based cancer vaccine significantly lowered the chance of death or recurrence of cancer in high-risk melanoma patients.
The findings constitute a substantial justification for Moderna ( NASDAQ:MRNA ) and a step in the business’s aspirations to move beyond its current position as a Covid-19 vaccine company.
It could be the beginning of a significant shift in cancer treatment, in which mRNA-based personalized cancer vaccines are given in combination with established checkpoint inhibitors like Keytruda. Suppose the results hold up in a planned Phase 3 trial in the same category of patients, and similar tests are expected in other indications. In that case, it could represent the beginning of a significant shift in cancer treatment.
Shortly before the clinical trial findings were revealed on Monday, Stephane Bancel, the Chief Executive Officer of Moderna, was quoted in Barron’s as saying, “I think this is as big of a step for patients as Keytruda was.”
The clinical trial included 157 participants with high-risk melanoma who had previously undergone surgery to remove a tumor. The participants in the trial were randomly assigned to one of two groups: one group received only Keytruda, an immuno-oncology drug developed by Merck (MRK) that revolutionized the treatment of cancer when it was first introduced in 2014, and the other group received Keytruda in addition to mRNA-4157, a personalized cancer vaccine developed by Moderna. The trial was carried out on one hundred and fifty patients.
Patients who received mRNA-4157 in addition to Keytruda had a mortality risk or recurrence risk that was 44% lower than those who received Keytruda on its own. The result was significant according to the ...
Click here to read the full article on PressReach.com .Subscribe to the PressReach RSS feeds:
- Featured News RSS feed
- Investing News RSS feed
- Daily Press Releases RSS feed
- Trading Tips RSS feed
- Investing Videos RSS feed
Follow PressReach on Twitter
Follow PressReach on TikTok
Follow PressReach on Instagram
Subscribe to us on Youtube